Doxercalciferol
 | |
| Names | |
|---|---|
| IUPAC name
(1S,3R,5Z,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraene-1,3-diol | |
| Other names
1-Hydroxyergocalciferol; 1-Hydroxyvitamin D2; 1α-Hydroxyergocalciferol; 1α-Hydroxyvitamin D2; Hectorol; TSA 840 | |
| Identifiers | |
54573-75-0  | |
| ChEMBL | ChEMBL1200810  |
| ChemSpider | 4444554 |
| 2790 | |
| Jmol interactive 3D | Image |
| PubChem | 5281107 |
| UNII | 3DIZ9LF5Y9 |
| |
| |
| Properties | |
| C28H44O2 | |
| Molar mass | 412.66 g·mol−1 |
| Pharmacology | |
| ATC code | H05 |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| verify (what is ?) | |
| Infobox references | |
Doxercalciferol (trade name Hectorol) is drug for secondary hyperparathyroidism and metabolic bone disease.[1] It is a synthetic analog of ergocalciferol (vitamin D2). It suppresses parathyroid synthesis and secretion.[2]
References
- ↑ Sprague S M; Ho L T (2002). "Oral doxercalciferol therapy for secondary hyperparathyroidism in a peritoneal dialysis patient". Clinical nephrology 58 (2): 155–160. PMID 12227689.
- ↑ "Doxercalciferol". Drugs.com.
| ||||||||||
This article is issued from Wikipedia - version of the Monday, November 30, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.